Targeting interleukin-6 in rheumatoid arthritis (Q38086137)

28 August 2017

title

Targeting interleukin-6 in rheumatoid arthritis (English)

1 reference

28 August 2017

0 references

1 reference

2

1 reference

28 August 2017

Md Yuzaiful Md Yusof

1

1 reference

28 August 2017

publication date

1 March 2013

1 reference

full work available at URL

28 August 2017

http://eprints.whiterose.ac.uk/85075/

content deliverer

White Rose Research Online

0 references

published in

Drugs

1 reference

28 August 2017

volume

73

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

341-356

1 reference

The epidemiology of rheumatoid arthritis

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

The role of interleukin 6 in the pathophysiology of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Molecular cloning and expression of an IL-6 signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Tocilizumab in refractory adult Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Integrated safety in tocilizumab clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

The role of tocilizumab in the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Total cholesterol and LDL levels decrease before rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Interleukin-6 stimulates lipolysis and fat oxidation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Assessing the safety of biologic agents in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0018-2

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

21 January 2018

1 reference

12 December 2020

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

1 reference

12 December 2020

Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA)

1 reference

12 December 2020

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium

1 reference

12 December 2020

Therapeutic effect of tocilizumab on two patients with polymyositis

1 reference

12 December 2020

Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study

1 reference

12 December 2020

Assessing remission in clinical practice

1 reference

12 December 2020

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

1 reference

12 December 2020

Comparison of composite disease activity indices for rheumatoid arthritis

1 reference

12 December 2020

"Arthritis specific" global health analog scales assess "generic" health related quality-of-life in patients with rheumatoid arthritis.

1 reference

12 December 2020

Angiogenesis in rheumatoid arthritis

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage

1 reference

12 December 2020

Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody

1 reference

12 December 2020

Demyelinating events in rheumatoid arthritis after drug exposures

1 reference

12 December 2020

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

1 reference

12 December 2020

Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention.

1 reference

12 December 2020

Tocilizumab treatment for neuro-Behcet's disease, the first report

1 reference

12 December 2020

Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants

1 reference

12 December 2020

Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis

1 reference

12 December 2020

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

12 December 2020

Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis

1 reference

12 December 2020

Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow

1 reference

12 December 2020

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of s

1 reference

12 December 2020

Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI

1 reference

12 December 2020

Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series

1 reference

12 December 2020

The health assessment questionnaire 1992: status and review

1 reference

12 December 2020

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

1 reference

12 December 2020

10.1007/S40265-013-0018-2

Identifiers

DOI

1 reference

10.1007/S40265-013-0018-2

28 August 2017

Altmetric DOI

0 references

Dimensions Publication ID

1008400750

0 references

Fatcat ID

release_sedlektwh5fs7bwvr22m2tblxy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sedlektwh5fs7bwvr22m2tblxy

24 November 2022

mapped directly with Wikidata item

1 reference